Does the FDA guidance affect perimenopause care

DISCLOSURE: Voshell’s Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

The short answer is: No, recent FDA guidance does not restrict or reduce access to standard, commercially available hormone therapy for perimenopause. It mainly clarifies safety expectations for all hormone products, especially compounded ones, and it does not change how clinicians prescribe HRT for symptoms.

How FDA guidance fits into perimenopause care

According to FDA.gov, the FDA’s role is to make sure hormone products sold in the U.S. are proven, consistent, and safe. Their guidance focuses on how hormones must be tested, labeled, and monitored. This applies to estrogen and progesterone used during perimenopause, but it does not limit your ability to receive treatment. Instead, it reinforces standards that protect women.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

Here is what it means in real life:

• Commercially available hormones remain the first-line option: According to FDA.gov, products like estradiol patches, gels, creams, and micronized progesterone capsules are fully supported by the FDA and remain available for perimenopause symptoms such as hot flashes, night sweats, sleep changes, and cycle instability.
• Dosing stays individualized: The guidance does not force a "one-size-fits-all" plan. A qualified prescriber may still adjust dose, route, and timing based on symptoms, age, cycle pattern, and personal risk factors.
• No ban on HRT: According to the FDA-approved prescribing information for estradiol and progesterone products, these therapies remain available for perimenopause and may be appropriate for many women when started at the correct dose and monitored by a qualified prescriber.
• Compounded hormone products receive extra scrutiny: According to FDA.gov, the FDA reminds clinicians that compounded hormones (often marketed as "bioidentical") are not tested for purity or consistency prior to dispensing. This does not affect women using standard commercially available estradiol and progesterone.
• Safety guidance clarifies known risks: According to FDA Drug Safety Communication, long-known points are restated: use the lowest effective dose, check for contraindications, and pair systemic estrogen with progesterone if you still have a uterus. None of this is new, and none of it blocks treatment.

How this affects your perimenopause choices

You may still start HRT in perimenopause if you and a qualified prescriber agree it fits your symptoms and health profile. According to FDA.gov, FDA guidance does not change when you may start, which hormones are used, or how long you may stay on them. It simply ensures that the products you receive are well-studied, consistent, and subject to regulatory oversight.

The bottom line: FDA guidance supports perimenopause care within established safety standards; it does not restrict it. Your options for relief remain open and may be discussed with a qualified prescriber based on your individual circumstances.